Your browser doesn't support javascript.
loading
Deep Phenotyping of CD11c+ B Cells in Systemic Autoimmunity and Controls.
Rincon-Arevalo, Hector; Wiedemann, Annika; Stefanski, Ana-Luisa; Lettau, Marie; Szelinski, Franziska; Fuchs, Sebastian; Frei, Andreas Philipp; Steinberg, Malte; Kam-Thong, Tony; Hatje, Klas; Keller, Baerbel; Warnatz, Klaus; Radbruch, Andreas; Lino, Andreia C; Schrezenmeier, Eva; Dörner, Thomas.
Afiliación
  • Rincon-Arevalo H; Department of Nephrology and Intensive Medical Care, Charité- Universitätsmedizin Berlin, Berlin, Germany.
  • Wiedemann A; Department of Rheumatology and Clinical Immunology, Charité- Universitätsmedizin Berlin, Berlin, Germany.
  • Stefanski AL; Deutsches Rheumaforschungszentrum, Berlin, Germany.
  • Lettau M; Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Instituto de Investigaciones Médicas, Universidad de Antioquia UdeA, Medellín, Colombia.
  • Szelinski F; Department of Rheumatology and Clinical Immunology, Charité- Universitätsmedizin Berlin, Berlin, Germany.
  • Fuchs S; Department of Rheumatology and Clinical Immunology, Charité- Universitätsmedizin Berlin, Berlin, Germany.
  • Frei AP; Department of Rheumatology and Clinical Immunology, Charité- Universitätsmedizin Berlin, Berlin, Germany.
  • Steinberg M; Department of Rheumatology and Clinical Immunology, Charité- Universitätsmedizin Berlin, Berlin, Germany.
  • Kam-Thong T; Deutsches Rheumaforschungszentrum, Berlin, Germany.
  • Hatje K; Roche Pharma Research and Early Development, Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.
  • Keller B; Roche Pharma Research and Early Development, Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.
  • Warnatz K; Roche Pharma Research and Early Development, Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.
  • Radbruch A; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Lino AC; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Schrezenmeier E; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, Medical Center-University of Freiburg, Freiburg im Breisgau, Germany.
  • Dörner T; Center for Chronic Immunodeficiency (CCI), Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany.
Front Immunol ; 12: 635615, 2021.
Article en En | MEDLINE | ID: mdl-33777025
ABSTRACT
Circulating CD11c+ B cells are a key phenomenon in certain types of autoimmunity but have also been described in the context of regular immune responses (i.e., infections, vaccination). Using mass cytometry to profile 46 different markers on individual immune cells, we systematically initially confirmed the presence of increased CD11c+ B cells in the blood of systemic lupus erythematosus (SLE) patients. Notably, significant differences in the expression of CD21, CD27, and CD38 became apparent between CD11c- and CD11c+ B cells. We observed direct correlation of the frequency of CD21-CD27- B cells and CD21-CD38- B cells with CD11c+ B cells, which were most pronounced in SLE compared to primary Sjögren's syndrome patients (pSS) and healthy donors (HD). Thus, CD11c+ B cells resided mainly within memory subsets and were enriched in CD27-IgD-, CD21-CD27-, and CD21-CD38- B cell phenotypes. CD11c+ B cells from all donor groups (SLE, pSS, and HD) showed enhanced CD69, Ki-67, CD45RO, CD45RA, and CD19 expression, whereas the membrane expression of CXCR5 and CD21 were diminished. Notably, SLE CD11c+ B cells showed enhanced expression of the checkpoint molecules CD86, PD1, PDL1, CD137, VISTA, and CTLA-4 compared to HD. The substantial increase of CD11c+ B cells with a CD21- phenotype co-expressing distinct activation and checkpoint markers, points to a quantitative increased alternate (extrafollicular) B cell activation route possibly related to abnormal immune regulation as seen under the striking inflammatory conditions of SLE which shows a characteristic PD-1/PD-L1 upregulation.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos B / Activación de Linfocitos / Síndrome de Sjögren / Autoinmunidad / Inmunofenotipificación / Antígeno CD11c / Citometría de Flujo / Lupus Eritematoso Sistémico Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Humans Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos B / Activación de Linfocitos / Síndrome de Sjögren / Autoinmunidad / Inmunofenotipificación / Antígeno CD11c / Citometría de Flujo / Lupus Eritematoso Sistémico Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Humans Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Alemania